• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Lion Biotechnologies Partners with Cancer Center for Trials

    Bryan Mc Govern
    Apr. 19, 2017 09:42AM PST
    Biotech Investing

    Lion Biotechnologies will partner with The University of Texas MD Anderson Cancer Center involving various cancer clinical trials.

    Lion Biotechnologies (NASDAQ:LBIO) will partner with The University of Texas MD Anderson Cancer Center involving various cancer clinical trials.
    As quoted in the press release:

    In addition, preclinical research will explore the expansion of TIL in other rare tumor types.
    In the clinical trials, TIL therapy will be evaluated in multiple solid tumor cancers using two different TIL manufacturing processes. The trials will be designed by the Lion and MD Anderson joint steering committee and conducted at MD Anderson. A related preclinical research collaboration will focus on the expansion of TIL from additional tumor types to identify new indications for future clinical research. Lion and MD Anderson will both have manufacturing responsibilities for production of TILs used in the planned cellular therapy trials.
    “We are excited to form this strategic alliance with MD Anderson. Together, we expect to generate data that will support the pursuit of additional pipeline indications to complement our ongoing Lion-sponsored TIL clinical programs in metastatic melanoma, head and neck and cervical cancers,” said Maria Fardis, PhD, MBA, Lion Biotechnologies’ President and Chief Executive Officer. “This collaboration leverages Lion’s strong expertise in TIL therapy and our expanding TIL manufacturing capacity, with MD Anderson’s deep experience in developing novel methods for generating TIL and innovative clinical care in treating oncology patients with unmet needs.”
    “This TIL-based technology is yet another tool in MD Anderson’s ongoing efforts to provide new therapies for our patients,” said Amir Jazaeri, M.D., associate professor of Gyn/Onc and Reproductive Medicine at MD Anderson. “It is our hope that this area of study will further treatment options for multiple types of cancer.”
    About Lion Biotechnologies, Inc.
    Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company’s lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute, MD Anderson and Moffitt Cancer Center. For more information, please visit https://www.lionbio.com.
    About MD Anderson
    The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 47 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for nine of the past 10 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

    Click here to read the full press release.

    Source: www.marketwired.com

    clinical-stage biotechnologylion biotechnologiesnational institutes of healthclinical stage biotechnology companyclinical trialscell therapy
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×